Vertex Pharmaceuticals Quarterly Balance Sheet
NASDAQ: VRTXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Vertex Pharmaceuticals financial position
As of Jun 30, 2026, Vertex Pharmaceuticals reported total assets of $27.42 billion, up 14.1% from a year earlier against total liabilities of $7.18 billion. Shareholders' equity stood at $20.25 billion, or 73.8% of assets. The company held $6.14 billion in cash and equivalents.
The current ratio (current assets divided by current liabilities) was 3.19, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
Vertex Pharmaceuticals balance sheet (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 6.14B | 5.49B | 5.08B | 4.94B | 4.97B | 4.67B | 4.57B | 5.24B | 4.58B | 9.16B | 10.37B | 11.11B |
| Short-Term Investments | 1.71B | 1.75B | 1.52B | 1.35B | 1.41B | 1.53B | 1.55B | 1.29B | 1.22B | 1.01B | 849.20M | 818.00M |
| Receivables | 2.13B | 2.00B | 2.05B | 1.95B | 1.89B | 1.81B | 1.61B | 1.75B | 1.66B | 1.79B | 1.56B | 1.54B |
| Inventory | 1.77B | 1.77B | 1.69B | 1.63B | 1.50B | 1.36B | 1.21B | 1.08B | 914.60M | 813.10M | 738.80M | 688.70M |
| Total Current Assets | 12.54B | 11.73B | 11.20B | 10.57B | 10.43B | 10.01B | 9.60B | 9.80B | 8.94B | 13.29B | 14.14B | 14.70B |
| Property, Plant & Equipment | 1.67B | 1.61B | 1.52B | 1.43B | 1.34B | 1.30B | 1.23B | 1.12B | 1.20B | 1.17B | 1.16B | 1.12B |
| Goodwill | 1.09B | 1.09B | 1.09B | 1.09B | 1.09B | 1.09B | 1.09B | 1.09B | 1.09B | 1.09B | 1.09B | 1.09B |
| Intangible Assets | 412.80M | 418.50M | 424.20M | 429.80M | 435.50M | 441.20M | 825.90M | 831.60M | 837.50M | 834.90M | 839.90M | 603.60M |
| Long-Term Investments | 5.79B | 5.75B | 5.71B | 5.72B | 5.65B | 5.16B | 5.11B | 4.70B | 4.39B | 4.38B | 2.50B | 1.70B |
| Total Assets | 27.42B | 26.48B | 25.64B | 24.86B | 24.04B | 22.88B | 22.53B | 22.24B | 20.13B | 23.92B | 22.73B | 21.73B |
| Accounts Payable | 429.50M | 489.30M | 461.70M | 420.30M | 442.30M | 445.00M | 413.00M | 395.80M | 327.90M | 351.40M | 364.90M | 375.90M |
| Total Current Liabilities | 3.94B | 3.88B | 3.86B | 4.48B | 4.14B | 3.78B | 3.56B | 3.97B | 3.55B | 3.80B | 3.55B | 3.60B |
| Total Liabilities | 7.18B | 7.12B | 6.98B | 7.54B | 6.86B | 6.38B | 6.12B | 6.61B | 5.36B | 5.37B | 5.15B | 5.21B |
| Shareholders' Equity | 20.25B | 19.36B | 18.67B | 17.32B | 17.18B | 16.50B | 16.41B | 15.63B | 14.77B | 18.55B | 17.58B | 16.51B |
| Retained Earnings | 15.69B | 14.59B | 13.56B | 12.37B | 11.29B | 10.25B | 9.61B | 8.69B | 7.65B | 11.24B | 10.14B | 9.17B |
| Net Cash (Debt) | 7.85B | 7.25B | 6.61B | 6.29B | 6.38B | 6.20B | 6.12B | 6.52B | 5.80B | 10.17B | 11.22B | 11.93B |
| Shares Outstanding | 253.35M | 254.16M | 253.99M | 253.95M | 256.29M | 256.97M | 256.94M | 257.74M | 258.02M | 258.30M | 257.70M | 257.83M |
This table shows 12 quarterly periods of Vertex Pharmaceuticals's balance sheet, from Q2 2026 back to Q3 2023, across 19 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow VRTX's reporting calendar. What is a balance sheet?